Orthocell's September Quarter Revenue Meets Fiscal 2026 Expectations, Euroz Hartleys Says

MT Newswires Live

Oct 03

Orthocell's (ASX:OCC) record revenue of AU$3 million for the September quarter, up 9.1% quarter over quarter, is consistent with Euroz Hartleys' fiscal 2026 revenue estimate of AU$14.4 million, according to a Thursday note from the investment advisory firm.

The first-quarter growth was due to higher sales of Remplir, the company's nerve repair product, in Australia and Singapore, Euroz Hartleys said.

Though Remplir did not have a material revenue contribution from the US market, Euroz Hartleys noted that the company expects US sales to start ramping up from the December quarter.

"The US rollout of Remplir remains central to our investment thesis," the investment advisory firm added.

Euroz Hartleys maintained Orthocell's hold rating and raised its price target to AU$1.36 from AU$1.30.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/news/2572631522"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2572631522\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2572631522?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-10-03 08:34","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2572631522","market":"us","top_or_hot":-1,"title":"Orthocell's September Quarter Revenue Meets Fiscal 2026 Expectations, Euroz Hartleys Says","media":"MT Newswires Live","content":"<html><body><p> Orthocell's (ASX:OCC) record revenue of AU$3 million for the September quarter, up 9.1% quarter over quarter, is consistent with <a href=\"https://laohu8.com/S/EZL.AU\">Euroz</a> Hartleys' fiscal 2026 revenue estimate of AU$14.4 million, according to a Thursday note from the investment advisory firm.</p><p>The first-quarter growth was due to higher sales of Remplir, the company's nerve repair product, in Australia and Singapore, Euroz Hartleys said.</p><p>Though Remplir did not have a material revenue contribution from the US market, Euroz Hartleys noted that the company expects US sales to start ramping up from the December quarter.</p><p>\"The US rollout of Remplir remains central to our investment thesis,\" the investment advisory firm added.</p><p>Euroz Hartleys maintained Orthocell's hold rating and raised its price target to AU$1.36 from AU$1.30.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Orthocell's September Quarter Revenue Meets Fiscal 2026 Expectations, Euroz Hartleys Says</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nOrthocell's September Quarter Revenue Meets Fiscal 2026 Expectations, Euroz Hartleys Says\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2025-10-03 08:34</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Orthocell's (ASX:OCC) record revenue of AU$3 million for the September quarter, up 9.1% quarter over quarter, is consistent with <a href=\"https://laohu8.com/S/EZL.AU\">Euroz</a> Hartleys' fiscal 2026 revenue estimate of AU$14.4 million, according to a Thursday note from the investment advisory firm.</p><p>The first-quarter growth was due to higher sales of Remplir, the company's nerve repair product, in Australia and Singapore, Euroz Hartleys said.</p><p>Though Remplir did not have a material revenue contribution from the US market, Euroz Hartleys noted that the company expects US sales to start ramping up from the December quarter.</p><p>\"The US rollout of Remplir remains central to our investment thesis,\" the investment advisory firm added.</p><p>Euroz Hartleys maintained Orthocell's hold rating and raised its price target to AU$1.36 from AU$1.30.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK7067","symbol_name":"生物科技","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2572631522","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2572631522","pubTimestamp":1759451674,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Orthocell's  record revenue of AU$3 million for the September quarter, up 9.1% quarter over quarter, is consistent with Euroz Hartleys' fiscal 2026 revenue estimate of AU$14.4 million, according to a Thursday note from the investment advisory firm.The first-quarter growth was due to higher sales of Remplir, the company's nerve repair product, in Australia and Singapore, Euroz Hartleys said.Though Remplir did not have a material revenue contribution from the US market, Euroz Hartleys noted that the company expects US sales to start ramping up from the December quarter.\"The US rollout of Remplir remains central to our investment thesis,\" the investment advisory firm added.Euroz Hartleys maintained Orthocell's hold rating and raised its price target to AU$1.36 from AU$1.30.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK7067":"生物科技","OCC.AU":"ORTHOCELL LTD","BK7508":"医药生物股"},"translate_title":"Euroz Hartleys表示，Orthocell 9月份季度收入符合2026财年预期","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"OCC.AU":1},"content_text":"Orthocell's (ASX:OCC) record revenue of AU$3 million for the September quarter, up 9.1% quarter over quarter, is consistent with Euroz Hartleys' fiscal 2026 revenue estimate of AU$14.4 million, according to a Thursday note from the investment advisory firm.The first-quarter growth was due to higher sales of Remplir, the company's nerve repair product, in Australia and Singapore, Euroz Hartleys said.Though Remplir did not have a material revenue contribution from the US market, Euroz Hartleys noted that the company expects US sales to start ramping up from the December quarter.\"The US rollout of Remplir remains central to our investment thesis,\" the investment advisory firm added.Euroz Hartleys maintained Orthocell's hold rating and raised its price target to AU$1.36 from AU$1.30.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}